Generic Drugs Packaging Pharma Companies Production 
World of DTC Marketing
APRIL 12, 2021
A blood-thinning agent, heparin, had been adulterated due to the product license holder (Baxter) procuring a toxic substance that had been illegally substituted for the genuine registered material. The adulterated product was found to have caused nine patient deaths and 574 serious adverse events (SAEs).
Pharmaceutical Technology
JULY 15, 2022
California’s budget documents give few details about the tender process, but state that CalRx will spend $50 million to partner with a contract manufacturer to develop biosimilar insulin products in vial and pen form. This CMO will be responsible for product roll-out and distribution. In-house manufacturing the norm.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Discovery World
MARCH 29, 2023
Regulatory data protection (RDP) period RDP refers to the time when generic drug makers cannot refer to an innovator drug’s data to obtain a marketing authorisation 2. This looks like it may change shape in the future for the region, if the proposal put forward by the commission is adopted.
Pharmaceutical Technology
SEPTEMBER 23, 2022
These companies often have limited in-house resources for product development or scale-up, and so depend on CDMO partnerships to achieve development milestones. As both a CDMO and a manager of CMOs, Avéma Pharma Solutions sees the following trends emerging to build the CDMO of the future. Narrower product focus.
Pharmaceutical Technology
MARCH 22, 2023
During the pandemic, the shortage of basic drugs such as paracetamol in key EU countries led to growing calls to push local drug manufacturing to ensure a smooth supply and to minimise shortages. Despite having large biopharmaceutical companies on home ground, the UK and France experienced major shortages and supply chain issues.
Expert insights. Personalized for you.
187 
Let's personalize your content